Adeleh Yarmohammadi, None;
Sasan Moghimi, None;
Linda Zangwill, Heidelberg (F), Heidelberg (P), National Eye Institute (F), Optouve (F), Topcon (F), Zeiss (F), Zeiss (P);
Huiyuan Hou, None;
James Proudfoot, None;
Christopher Bowd, None;
Fazio Massimo, Eyesight Foundation of Alabama (F), GmbH (F), Heidelberg (F), National Eye Institute (F), Research to prevent blindness (F);
Haft Michael, None;
De Moraes Carlos, Belite (C), Glimedix (C), Heidelberg (R), Novartis (C), Perfuse (C), Reichert (C), Topcon (R), Zeiss (C);
Christopher Girkin, EyeSight Foundation of Alabama (F), GmbH (F), Heidelberg (F), National Eye Institute (F), Research to prevent blindness (F);
Jeffrey Leibmann, Aerie (C), Alcon (C), Allergan (C), Bausch & Lomb (F), Bausch & Lomb (C), Eyenova (C), Galimedix (C), GmbH (C), Heidelberg (C), Heidelberg (F), Novartis (C), Optovue (F), Reichert (C), Reichert (F), Research to prevent blindness (F), Topcon (F), Valeant (C), Zeiss (C), Zeiss (F);
Robert Weinreb, Aerie (C), Allergan (C), Bausch & Lomb (C), Bausch & Lomb (F), Centervue (F), Eyenova (C), Heidelberg (F), Konan (F), Optovue (F), Toromedes (P), Zeiss-meditec (F), Zeiss-meditec (P)